B+
Bull case
16%
Probability
Target price
$10.50
+195.8% vs current
NTRB
NutribandBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
49%
Probability
Target price
$3.10
-12.7% vs current
B-
Bear case
35%
Probability
Target price
$1.70
-52.1% vs current
AI sentiment snapshot
Latest data as of 2026-06-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+55.8
Score
AI commentary
This remains a cautious monitoring update rather than a clean post-earnings thesis shift. Primary-source notes support the AVERSA regulatory-preparation and filing-monitoring context, but the packet does not provide a verified June 1 earnings release, analyst revision, direct peer confirmation, or clear post-print price-reaction evidence. The weak direct-peer set and incomplete earnings follow-up evidence keep conviction capped and leave the setup cautiously negative until a verified IR release, filing, transcript, or stronger revision signal closes the gap.
RankAlpha Sentiment Codex - 2026-06-02
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-06-30eventBrand-name submission is a near-term regulatory housekeeping stepMedium impact
Nutriband said it selected a worldwide commercial brand-name candidate for its lead abuse-deterrent fentanyl patch and plans to submit the name and labeling to the FDA and other regulators for review/approval [#8-K-2026-04-07]. This is supportive for the eventual NDA package, but it is not a commercial inflection on its own.
2026-10-31catalystFunding discipline and dilution risk remain the main overhangHigh impact
The October 31, 2025 10-Q showed cash and cash equivalents of $5.31 million, nine-month AVERSA Fentanyl R&D expense of $1.70 million, and a nine-month net loss of $7.26 million, so funding capacity for continued clinical and regulatory work remains a monitoring item rather than a confirmed upside catalyst [#10-Q-2025-12-11].
2027-04-30catalystAVERSA Fentanyl remains the core long-horizon value driverHigh impact
The latest annual report remains the main primary-source anchor for Nutriband's development-stage profile and AVERSA Fentanyl monitoring, but the packet does not provide a detailed dated clinical or approval milestone beyond the filing context [#10-K-2026-04-29]. That keeps the long-dated optionality intact while leaving timing and execution visibility limited.
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology